Corporate News
Payment received
11 July 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc (“Abingdon”) in relation to the manufacture and supply of AbC-19™ Rapid tests, a COVID-19 lateral flow antibody test.
The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care (“DHSC”) on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon.
Contacts:
| Omega Diagnostics Group PLC | www.omegadx.com |
| Jag Grewal Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | |
| Alice Lane/ Harriet Ward (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Applegarth | Mob: 07584 391 303 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com
Latest Share Price
Investor News
-
21 January 2025
Omega Diagnostics court summons -
16 January 2025
Settlement of DHSC Claim